Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.

India has achieved replacement level fertility: Minister Pawar

Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Bulk Drug Park in the country :PIB

The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.

SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData

This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines

AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy

AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.

Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.